353544-77-1

Basic information

• Product Name: N-(1-benzyl-4-piperidyl)-N-(1H-5-indazolyl)-amine
• Synonyms: N-(1-benzyl-4-piperidyl)-N-(1H-5-indazolyl)-amine
• CAS NO: 353544-77-1
• Molecular Weight: 306.41
• Mol File: 353544-77-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N-(1-benzyl-4-piperidyl)-N-(1H-5-indazolyl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1-benzyl-4-piperidyl)-N-(1H-5-indazolyl)-amine(353544-77-1)
• EPA Substance Registry System: N-(1-benzyl-4-piperidyl)-N-(1H-5-indazolyl)-amine(353544-77-1)

Safety Data

• Hazardous Substances Data: 353544-77-1(Hazardous Substances Data)

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 19335-11-6 1H-indazol-5-ylamine 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 353547-58-7 N₁-(1-Benzyl-4-piperidyl)-N₁-(1H-5-indazolyl)acetamide 

Relevant articles and documents

Design and synthesis of Rho kinase inhibitors (II)

In a previous study, we identified several structurally unrelated scaffolds of the Rho kinase inhibitor using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. 1H-Indazole is one of the candidate scaffolds on which a new series of potent Rho kinase inhibitors could be developed. In this study, the detailed structure-activity relationship of 1H-indazole analogues was studied. During this study, we found that the cell-free enzyme inhibitory potential of Rho kinase inhibitors having the 1H-indazole scaffold did not necessarily correlate with their inhibitory potential toward the chemotaxis of cultured cells. The choice of the linker substructure was shown to be an important factor for the 1H-indazole analogues to inhibit the chemotaxis of cells. Optimization of the 1H-indazole inhibitors with respect to the in vitro inhibition of monocyte chemotaxis induced by MCP-1 was carried out. The inhibitory potential was improved both in the cell-free enzyme assay and in the chemotaxis assay.

Design and synthesis of Rho kinase inhibitors (I)

Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure-activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.

NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME

An objective of the present invention is to provide compounds having Rho kinase inhibitory activity. The compounds according to the present invention are those represented by formula (I) or pharmaceutically acceptable salts or solvates thereof:Het-X-Z wherein Het represents a monocyclic or bicyclic heterocyclic group containing at least one nitrogen atom, for example, pyridyl or phthalimide; X represents group (i) -NH-C(=O)-NH-Q1-, group (ii) -NH-C(=O)-Q2-, wherein Q1 and Q2 represent a bond, alkylene, or alkenylene, or the like; and Z represents hydrogen, halogen, a monocyclic, bicyclic, or tricyclic carbocyclic group, a heterocyclic group or the like, for example, optionally substituted phenyl.